Death from infection: reducing the risk in patients with CLL
While the outcome for patients with chronic lymphocytic leukemia (CLL) has significantly improved over the last 30 years due to effective treatment options, the number of patients with CLL dying as a ...
Author: VJHemOnc
Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel revelations in CLL biology with venetoclax/ibrutinib
The BCL2 inhibitor venetoclax is just one example of a new therapeutic agent that has allowed patients with chronic lymphocytic leukemia (CLL) to reach measurable residual disease (MRD) negativity, th...
Author: VJHemOnc
Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Using MRD to inform CLL treatment in a clinical trial
Achievement of a complete response and measurable residual disease (MRD) negativity are associated with improved survival in chronic lymphocytic leukemia (CLL). Pierre Feugier, MD, PhD, of the Centre ...
Author: VJHemOnc
Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel agents or imatinib for CML in the frontline setting?
With the many new second generation therapies for chronic myeloid leukemia (CML), there is some debate as to which therapy should be used in the first-line setting, and indeed whether the existing sta...
Author: VJHemOnc
Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Evolving treatment goals in CML
The aims of treatment for chronic myeloid leukemia (CML) have changed in recent years, as explained here by Susanne Saussele, MD, of the University of Mannheim, Mannheim, Germany. With the introductio...
Author: VJHemOnc
Added: 08/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Updates in CML: recent trials and novel agents
Highlights of promising clinical trials of novel agents for chronic myeloid leukemia (CML) are overviewed here by Susanne Saussele, MD, of the University of Mannheim, Mannheim, Germany. Discussed are ...
Author: VJHemOnc
Added: 08/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel agents in trials for AML: quizartinib and gilteritinib
At the 2018 European School of Haematology (ESH) Clinical Updates on Acute Leukaemias, held in Budapest, Hungary, Mark Levis, MD, PhD, from Sidney Kimmel Comprehensive Cancer Centre, Baltimore, MD, gi...
Author: VJHemOnc
Added: 08/02/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2018 Category: Cancer & Oncology Source Type: podcasts
Newly approved drugs for AML in the US
New drugs for acute myeloid leukemia (AML) are constantly being developed. In this video, recorded at the 23rd Congress of the European Hematological Association (EHA) 2018, held in Stockholm, Sweden,...
Author: VJHemOnc
Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Azacitidine with checkpoint inhibitors for AML and MDS
There has been growing evidence that the combination of hypomethylating agents like azacitidine with immune checkpoint inhibitors could be a highly potent treatment option in acute myeloid leukemia (A...
Author: VJHemOnc
Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Current and future aspirations of ERIC
In this video, Lydia Scarf, MD, of Vita-Salute San Raffaele University, Milan, Italy, describes the studies on chronic lymphocytic leukemia (CLL) currently being undertaken by the European Research I...
Author: VJHemOnc
Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts
The importance of AML education amongst practitioners
A large proportion of acute myeloid leukemia (AML) patients are treated by non-specialist community oncologists, who may not have the time or energy to attend conferences or lectures presenting specia...
Author: VJHemOnc
Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Epigenetic therapies in AML: current and future landscape
Epigenetic therapies are constantly developing in the field of acute myeloid leukemia (AML). In this video, recorded at the 23rd Congress of the European Hematological Association (EHA) 2018, held in ...
Author: VJHemOnc
Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Immunotherapy in AML: azacitidine plus checkpoint inhibitors
Acute myeloid leukemia (AML) has shown good responses to immunotherapies, including monoclonal antibodies, immune checkpoint inhibitors and bispecific antibodies. Here, Naval Daver, MD, of the MD Ande...
Author: VJHemOnc
Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Preclinical data for quizartinib plus MDM2 inhibitor in AML
Clinical trials have demonstrated the positive response rates for FLT3 inhibitors like quizartinib in relapsed FLT3-mutated acute myeloid leukemia (AML). A major problem for quizartinib monotherapy, h...
Author: VJHemOnc
Added: 07/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 30, 2018 Category: Cancer & Oncology Source Type: podcasts
ALL: recent immunotherapeutic developments
In this video, Ryan Cassaday, MD, of the University of Washington, Seattle, WA, gives an overview of recent developments in the field of acute lymphoblastic leukemia (ALL). He touches upon inotuzumab ...
Author: VJHemOnc
Added: 07/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 30, 2018 Category: Cancer & Oncology Source Type: podcasts
